Compare Heron Therapeutics Inc (HRTX) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Hershey Co — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Hershey Co trades at $162.74 (market cap $32.66B). The key difference: Hershey Co is far larger — about 480.2× Heron Therapeutics Inc's market cap, and Hershey Co pays a 3.57% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Hershey Co for 135 Days on average.
| HRTX | HSY | |
|---|---|---|
Market Cap | $68.01M | $32.66B |
Volume | 1,891,941 | 1,578,237 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $236.28 |
52-Week Low | $0.27 | $157.61 |
Typical Hold Time | 35 Days | 135 Days |
Enterprise Value | $174.75M | $37.79B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus targets $204.62 with 65.72% hold ratings, while recent news highlights dividend resumption and international leadership changes.
HSY offers value near 52-week lows with 25% upside to consensus target, supported by consistent earnings outperformance and brand strength. Key risks include cocoa cost pressures, margin compression from 2025 results, and technical bearish momentum. The dividend yield of 3.57% provides income support during market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
